CPMD · XBRL financial data

Cannapharmarx financial statements, every fiscal year

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CPMD's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	0	0	0	0	820	1,362
Cost of goods and services sold	—	—	—	—	3,755	3,447
Gross profit	—	—	—	—	(2,935)	(2,085)
Selling, general and administrative	—	—	—	—	117	—
General and administrative	478	2,135	853	2,227	117	490
Total operating expenses	15,978	14,486	2,993	5,212	671	1,263
Operating income (loss)	(15,978)	(14,486)	(2,993)	(5,212)	(3,606)	(3,348)
Interest expense	4,473	2,294	1,507	2,290	2,264	1,959
Other income (expense)	—	—	—	—	(6,275)	(7,784)
Income tax expense (benefit)	0	0	0	0	0	0
Net income (loss)	(20,451)	(19,890)	(8,832)	(8,531)	(9,906)	(11,131)
Earnings per share, basic USD per share	—	—	0.12	0.04	—	—
Earnings per share, diluted USD per share	—	—	0.12	0.04	(0.02)	(0.02)
Weighted average shares, basic thousands of shares	—	40,700	74,687	211,044	—	—
Weighted average shares, diluted thousands of shares	31,175	40,700	74,687	211,044	625,276	662,501

Fiscal years (CPMD's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	2	335	28	2	2	2
Accounts receivable	—	—	—	—	2	164
Inventory	—	—	—	—	996	1,115
Total current assets	1,931	468	30	100	1,019	1,311
Property and equipment, net	0	1,569	6	108	137	127
Right-of-use asset	—	—	0	—	5,161	5,580
Goodwill	6,370	0	—	—	—	—
Total assets	16,017	8,748	114	5,414	10,836	7,018
Accounts payable	903	2,448	3,129	6,883	4,784	5,470
Accrued liabilities	903	—	—	—	4,303	4,399
Total current liabilities	3,952	17,549	13,040	17,165	25,752	31,590
Lease liability, non-current	—	—	—	—	4,893	5,034
Total liabilities	11,163	17,549	13,040	22,759	30,645	37,172
Accumulated deficit	(57,442)	(77,332)	(86,164)	(94,695)	(101,184)	(112,316)
Total stockholders' equity	4,854	(8,802)	(12,926)	(17,344)	(19,810)	(30,154)
Total liabilities and equity	16,017	8,748	114	5,414	10,836	7,018
Common shares outstanding (cover page) thousands of shares	36,641	50,164	166,585	298,987	662,501	662,501

Fiscal years (CPMD's year ends in late December)

In thousands of dollars	FY 2019Dec 31, 2019	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(20,451)	(19,890)	(8,832)	(8,531)	(9,906)	(11,131)
Stock-based compensation	736	820	363	181	—	—
Net cash from operating activities	(3,795)	(564)	(2,415)	(1,448)	(1,697)	(789)
Purchases of property and equipment	5	—	—	—	0	6
Net cash from investing activities	(47)	0	494	(116)	0	794
Proceeds from issuing common stock	—	0	291	290	—	—
Share repurchases	99	0	—	—	—	—
Proceeds from long-term debt	1,550	848	584	913	363	—
Net cash from financing activities	3,266	825	1,340	1,405	1,699	(6)
Net change in cash	—	—	(307)	(25)	2	(0)

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cannapharmarx	0.6	276	(127)*	708.7M	0.0 quarters	Q2 FY26 10-QJun 30, 2026
Propanc Biopharma	832	not reported	(1,602)*	6.3M	0.5 quarters	Q4 FY26 10-KJun 30, 2026
MetaVia	12,634	not reported	(3,762)*	6.6M	3.4 quarters	Q2 FY26 10-QJun 30, 2026
Scorpius Holdings	582	not reported	(2,917)*	61.1M	0.2 quarters	Q3 FY25 10-QSep 30, 2025
Oragenics	3,864	not reported	(2,187)*	4.5M	1.8 quarters	Q2 FY26 10-QJun 30, 2026
Inhibitor Therapeutics	516	not reported	(775)*	173.8M	0.7 quarters	Q2 FY26 10-QJun 30, 2026
PTC Therapeutics	508,894	357,807	(25,311)*	83.5M	—	Q3 FY26 10-QSep 30, 2026
Nomad Power Solutions	12,670	not reported	(1,612)*	16.1M	7.9 quarters	Q2 FY26 10-QJun 30, 2026
Integrated Biopharma	4,471	not reported	(1,194)*	31.1M	3.7 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.